These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37019064)

  • 21. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Process Evaluation of Using Digital Health Technologies in Pharmaceutical Care in Low- and Middle-Income Countries: A Systematic Review of Quantitative and Qualitative Studies.
    Alfian SD; Insani WN; Puspitasari IM; Wawruch M; Abdulah R
    Telemed J E Health; 2023 Sep; 29(9):1289-1303. PubMed ID: 36749170
    [No Abstract]   [Full Text] [Related]  

  • 23. Application of a health technology assessment framework to digital health technologies that manage chronic disease: a systematic review.
    von Huben A; Howell M; Carrello J; Norris S; Wortley S; Ritchie A; Howard K
    Int J Technol Assess Health Care; 2021 Dec; 38(1):e9. PubMed ID: 34924061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?
    Edlin R; Hall P; Wallner K; McCabe C
    Value Health; 2014 Jun; 17(4):438-44. PubMed ID: 24969005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using and choosing digital health technologies: a communications science perspective.
    Ovretveit J; Wu A; Street R; Thimbleby H; Thilo F; Hannawa A
    J Health Organ Manag; 2017 Mar; 31(1):28-37. PubMed ID: 28260405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria.
    Iskrov G; Stefanov R
    Balkan Med J; 2016 Jan; 33(1):27-35. PubMed ID: 26966615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International practices in health technology assessment and public financing of digital health technologies: recommendations for Hungary.
    Mezei F; Horváth K; Pálfi M; Lovas K; Ádám I; Túri G
    Front Public Health; 2023; 11():1197949. PubMed ID: 37719722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.
    Jirawattanapisal T; Kingkaew P; Lee TJ; Yang MC
    Value Health; 2009; 12 Suppl 3():S4-11. PubMed ID: 20586980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
    Beresniak A; Dupont D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How can we improve patients' access to new drugs under uncertainties? : South Korea's experience with risk sharing arrangements.
    Lee B; Bae EY; Bae S; Choi HJ; Son KB; Lee YS; Jang S; Lee TJ
    BMC Health Serv Res; 2021 Sep; 21(1):967. PubMed ID: 34521408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement.
    Kim DS; Lee G; Cho H; Bae S
    Front Bioeng Biotechnol; 2021; 9():737504. PubMed ID: 34527662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of Digital Therapeutics on Current Health Technology Assessment Frameworks.
    Yan K; Balijepalli C; Druyts E
    Front Digit Health; 2021; 3():667016. PubMed ID: 34713140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrating environmental considerations in digital health technology assessment and procurement: Stakeholders' perspectives.
    Alami H; Rivard L; Lehoux P; Ag Ahmed MA; Fortin JP; Fleet R
    Digit Health; 2023; 9():20552076231219113. PubMed ID: 38074337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reimbursement Coverage and Pricing Systems for Single-Use Devices in Asia-Pacific: Japan, Taiwan, Korea, and Australia Compared.
    Lee SS; Symonds D; Kamogawa S; Sato M; Chiang E; Salole E
    Value Health Reg Issues; 2015 May; 6():126-129. PubMed ID: 29698183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mental health professionals views and the impact of COVID-19 pandemic on implementing digital mental health in China: A nationwide survey study.
    Zhang X; Lewis S; Chen X; Berry N; Bucci S
    Internet Interv; 2022 Dec; 30():100576. PubMed ID: 36185346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
    Kwon SH; Park SK; Byun JH; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Digital Health Technologies Applied by the Pharmaceutical Industry to Improve Access to Noncommunicable Disease Care in Low- and Middle-Income Countries.
    Heerdegen ACS; Cellini CM; Wirtz VJ; Rockers PC
    Glob Health Sci Pract; 2022 Oct; 10(5):. PubMed ID: 36316151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health technology assessment in India: the potential for improved healthcare decision-making.
    Kumar M; Ebrahim S; Taylor FC; Chokshi M; Gabbay J
    Natl Med J India; 2014; 27(3):159-63. PubMed ID: 25668089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of universal health insurance: lessons from South Korea.
    Moon S; Shin J
    Healthc Q; 2007; 10(3):116-30. PubMed ID: 17626554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.